Sanyou Biopharmaceuticals

Sanyou Biopharmaceuticals is an internationally leading biotechnology company focused on the research and development of innovative antibody drugs and related services. The company is committed to building a high-quality, high-throughput, integrated R&D and value transformation platform for innovative antibody drugs with international leadership. It aims to construct a business ecosystem for therapeutic, R&D, and diagnostic products and services, collaborating with global biopharmaceutical, diagnostic, and drug R&D companies to open new horizons in human disease diagnosis and treatment.Since its establishment, Sanyou Biopharmaceuticals has maintained rapid growth. As of May 2021, the company has a professional team of more than 160 people, with over 70% holding doctoral or master's degrees. The team possesses comprehensive experience in innovative drug R&D and industrialization. The company has established an advanced, integrated R&D laboratory for innovative antibody drugs spanning thousands of square meters within the "Shanghai Caohejing National High-Tech Park," equipped with state-of-the-art facilities. It encompasses 10 major functional modules and over 40 core technology platforms, including a series of ultra-large phage display antibody libraries, covering the discovery of innovative antibody drugs, antibody engineering modifications, in vivo and in vitro efficacy screening, druggability analysis of antibody drugs, construction of production cell lines, and process development.The company continuously launches new technologies, products, services, and scenarios that are "of the highest quality, fastest speed, and best cost-performance." Sanyou Biopharmaceuticals has established friendly business partnerships with over 150 pharmaceutical companies, drug R&D institutions, and diagnostic reagent product development companies worldwide.